Rhythm reports Q2 2026 IMCIVREE revenue of $71.3 million, strong HO launch uptake
More than 400 patient start forms were filed for IMCIVREE in acquired hypothalamic obesity as RM-718 posted early efficacy data in the same disease.
Rhythm Pharmaceuticals reported second quarter 2026 results on August 4, 2026, covering the period ended June 30, 2026. The company said more than 400 patient start forms had been received for IMCIVREE for acquired hypothalamic obesity from approximately 300 prescribers as of June 30, 2026, since FDA approval on March 19, 2026.1
Global IMCIVREE net product revenue was $71.3 million for the quarter, an increase of 19% on a sequential basis from the first quarter of 20261, and the number of patients on reimbursed therapy globally increased by greater than 20% compared to the first quarter of 2026.1 U.S. revenue was $51.0 million, or 72% of product revenue, up $14.1 million or 38% sequentially, driven primarily by increased patient demand for IMCIVREE in acquired HO and continued growth in Bardet-Biedl syndrome demand.1
Ex-U.S. revenue was $20.3 million, or 28% of product revenue, a sequential decrease of $(2.9) million or (13)% compared to the first quarter of 2026.1 The company separately incurred a $3.8 million retrospective charge associated with the Contribution M mechanism in France, of which $3.1 million related to revenue booked in periods prior to the second quarter of 2026.1 The number of reimbursed patients on IMCIVREE continued to increase in the second quarter of 2026.1
On the pipeline side, Rhythm disclosed preliminary Phase 1/2 Part C data for RM-718 in acquired HO. Eleven patients were enrolled in the ongoing open-label trial, with a -11.6% reduction in mean BMI from baseline at 16 weeks (n=7), compared with -10.1% BMI reduction with bivamelagon at 14 weeks and -10.1% with setmelanotide at 16 weeks.1 RM-718 was generally well tolerated, with the most common adverse events being injection site reactions, nausea, and vomiting.1
Net loss attributable to common stockholders was $(50.4) million for the second quarter of 2026, or $(0.73) per share, compared to $(48.0) million, or $(0.75) per share, a year earlier.1 Cash, cash equivalents and short-term investments were approximately $330.9 million as of June 30, 2026, down from $388.9 million at year-end 2025.1
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.